Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals . Braz. J. Pharm. Sci. [Internet]. 2011 Mar. 1 [cited 2024 May 13];47(1):31-8. Available from: https://revistas.usp.br/bjps/article/view/10853